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This document summarizes the rationale, equipment, protocol assays, internal quality control, data 
cleaning, external quality control, and procedures for the measurement and classification of 
inflammation at the Wave V home exam. Whenever possible, data collection and methods in Wave V 
mirrored those of Wave IV to ensure comparability of data between waves, although important inter-
Wave differences exist and are grey-highlighted herein. This document is one in a set of Wave V user 
guides. User guides are also available to describe protocols for the following biological measures in 
Wave V: 
 Anthropometrics 
 Cardiovascular Measures 
 Medication Use – Home Exam 
 Baroreflex Sensitivity & Hemodynamic Recovery 
 Glucose Homeostasis 
 Lipids 
 Renal Function 
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1. Introduction 
Wave IV measures of inflammation were based on dried blood spots collected using capillary finger 
prick.1 In contrast, Wave V measures of inflammation were based on venous blood collected via 
phlebotomy. The blood was collected by field examiners (FEs) certified in phlebotomy, chilled at 4°C 
during the remainder of the home exam, centrifuged immediately afterward, aliquoted into transport 
tubes, and then sent overnight to a laboratory for assay. 
 
Assayed Measures of Inflammation 
 
• High Sensitivity C-Reactive Protein (hsCRP, mg/L) 
 
Moreover, the restricted use Add Health Wave V data include eleven constructed measures designed to 
facilitate its analysis and interpretation: 
 
• Classification of hsCRP2 
• Count of common subclinical symptoms3 
• Count of common infectious or inflammatory diseases 
• NSAID/Salicylate medication use in the past 24 hours 
• NSAID/Salicylate medication use in the past 4 weeks 
• Cox-2 Inhibitor medication use in the past 4 weeks 
• Inhaled Corticosteroid medication use in the past 4 weeks 
• Corticotropin/Glucocorticoid medication use in the past 4 weeks 
• Anti-rheumatic/Anti-psoriatic medication use in the past 4 weeks 
• Immunosuppressive medication use in the past 4 weeks 
• Any Anti-inflammatory medication use in the past 4 weeks 
 
2. General Overview of Data Collection 
All Wave V venous blood samples were collected during home exams performed by FEs from two Add 
Health data collection partners: Examination Management Services, Inc. (2016–2017) and Hooper 
Holmes, Inc. (2018–2019). All FEs were trained and certified using a custom program specific to the Add 
Health protocol. FEs used a 7” Samsung Galaxy Tab 4 tablet to record and transmit data. An Add Health 
data collection application (Open Data Kit or ODK) installed on the tablet guided the FEs through the 
home exam protocol. In addition, FEs received a series of job aids, both on paper and on the tablet, to 
serve as quick reference guides when completing the protocol. Each tablet also contained an in-depth 
Add Health training manual that could be accessed at any time. 
 
FEs conducted home exams among previously consented respondents. All FEs were phlebotomy-
certified and had at least two years of experience collecting venous blood. Before home exams, FEs 
were sent a Visit Supply Kit that included a box for shipping blood to the lab and a Blood Collection Kit 
containing most required materials for the blood collection. FEs supplied additional materials, as needed 
(see section 3.2). Protocols for blood collection were dictated to FEs by the handheld 7” Samsung tablet 
used during all home exams. The tablet gave step-by-step directions for the blood collection and 
required FEs to enter information about the blood draw for each respondent. All respondents had the 
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option to decline part or all of the blood draw, although declining did not affect their ability to 
participate in the rest of the home exam.  Overall, 91.8% of the respondents agreed to and completed 
the blood draw.  Of the remainder, 6.5% refused, 1.3% agreed but the blood draw was unsuccessful, and 
< 1% had exams terminated before the blood draw (see the blood draw status variable H5BLOOD in the 
bdemo5 data set and codebook).   
 
Blood collection was the last step in the home exam. Afterwards, all collection tubes were inverted 8-10 
times to distribute the blood and contents of the tubes and then chilled at 4⁰ C (on ice or frozen cold 
packs) for up to two hours. Subsequent processing involved centrifuging specific tubes then aliquoting 
serum and plasma into color-coded transport tubes pre-labelled with unique barcode identifiers linking 
the blood to a particular respondent. Then the transport tubes were packaged in a Styrofoam Box with 
frozen cold packs and shipped overnight via FedEx to the Laboratory for Clinical Biochemistry Research 
(LCBR) at the University of Vermont. Overnight shipment enabled receipt by LCBR before 10:30 am the 
next morning.  Upon receipt, LCBR documented the arrival of the transport tubes, evaluated their 
condition, processed them, and either assayed the specimens or aliquoted and archived them in -80°C 
freezers.   
 
3. Whole Blood Collection 
3.1 Rationale 
 
Venous blood was collected to provide Add Health with the biological specimens necessary to assay and 
interpret a pre-specified panel of metabolic, hematologic, inflammatory, immune, and renal biomarkers, 
including the measure of hsCRP described herein. It also was collected to establish an archive of serum, 




Before exams, FEs were shipped a Visit Supply Kit (Exhibit 1) including (1) a cardboard Shipping Box with 
an inner Styrofoam Box and two cold packs for shipping collected samples to LCBR, (2) a large Tyvek 
envelope in which to ship the Shipping Box, and (3) a Blood Collection Kit for collecting blood.  The Blood 
Collection Kit contained: 
 
• Biohazard-labelled Ziploc bag 
• Latex-free gloves 
• 2”x2” gauze 
• Latex-free, Band-Aid type adhesive dressings 
• Latex-free, strap tourniquet 
• Alcohol prep pads, disposable pipets 
• Single-use vacutainer (blood collection) tube holder 
• 21-gauge Eclipse straight needle 
• 21-gauge butterfly needle 
• (3) disposable 3 ml graduated transfer pipets 
• (2) 8.5 ml serum separation transport (SST) vacutainer tubes 
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• (1) 6 ml sodium fluoride/potassium oxalate (NaFl/KOx)-containing vacutainer tube, if needed for 
the glucose sub-study (see Section 4.1.2.1) 
• (1) 3- or 4- ml potassium ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tube 
• (1) 10 ml EDTA-containing vacutainer tube 
• (1) 10 ml PAXgene vacutainer tube (containing 7.5 ml of preservative) 
• (4) 10 ml transport tubes with color coded caps  
• Extra barcode labels 
 
BD Biosciences (San Jose, CA) supplied all the vacutainer and transport tubes. As of February 2018, their 
3 ml EDTA vacutainer tube (Cat #367835) was no longer available, so Add Health switched to the 4 ml 
EDTA vacutainer tube (Cat #367844). 
 
 
Exhibit 1. Visit Supply and Blood Collection Kits 
 
 
FEs were responsible for providing ancillary materials for each home exam, including but not limited to a 
chux-type absorbent under pad, a sharps container, and a cooler with cold packs for keeping samples 
cold before packaging and shipping them to LCBR. 
 
3.3 General Protocol 
 
3.3.1 Blood Collection 
 
The blood draw was performed as the final stage of the home exam following collection of 
anthropometric, cardiovascular, and medication information. After confirming respondents were 
comfortable giving blood, respondents were asked to either sit or recline at their discretion. They also 
were asked if they had problems in the past with blood collection such as fainting, bleeding, or hard-to-
find veins. FEs were instructed to ensure the blood collection area was private, uncluttered, and fully 
prepared before beginning the blood draw. Preparation involved placing the chux pad, organizing the 
vacutainer tubes/supplies, preparing the cooler to accept the blood samples, and scanning the barcode 
located on the outside of the Blood Collection Kit. Scanning it automatically captured a unique, eight-
digit code, thereby linking the respondent to the transport tubes / labels within it, the corresponding 
ODK questionnaire data, and ultimately to LCBR results. 
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Following standard phlebotomy protocols, FEs asked respondents to identify an arm for collecting blood, 
applied the tourniquet to that arm, and identified a vein in the antecubital fossa for venipuncture. If no 
vein appeared suitable, FEs asked to try the opposite arm. Unless respondents had objections, 
venipuncture was performed on the best potential vein and whole blood was collected, as summarized 
below: 
 
• Put on nitrile gloves. 
• Have the respondent extend his/her arm on the protective pad, palm up and straight at the 
elbow. 
• Inspect the arm. Do not draw blood from an arm that has a rash, open sore, is swollen or shows 
signs of a recent venipuncture or hematoma. Do not draw blood from an arm that contains an 
arterial access such as a fistula or shunt.  
• Apply the tourniquet several inches above the elbow and palpate for a suitable vein.  
• Select a vein that is palpable and well-fixed to surrounding tissue. 
• Open the needle assembly unit and attach it to the vacutainer holder.  
• Ask the respondent to make a tight fist. Cleanse the area with an alcohol wipe using a circular 
motion and allow the area to air dry. 
• Remove the cover from the needle. 
• The vein should be fixed or held taut during the puncture. Push the needle firmly and 
deliberately into the vein. When firmly in the vein, blood appears in the tubing of the needle 
assembly past the end of the needle. 
• Quickly push the first vacutainer tube (using the sequence in the table above) onto the needle in 
the holder, puncturing the center of the stopper.  
• Release the tourniquet after the flow is established or if the respondent becomes 
uncomfortable. The respondent may open his/her fist once blood flow is established. 
• When the first vacutainer tube is filled to capacity, remove it from the holder and place the next 
vacutainer tube in the holder. 
• Gently invert each vacutainer tube 8-10 times immediately upon removing each one and while 
filling the next one. Repeat until all the desired vacutainer tubes are filled. 
• Place all filled vacutainer tubes directly into a cooler with ice or ice packs. 
• When the last vacutainer tube is filled, remove the tourniquet, carefully withdraw the needle, 
and cover the venipuncture site with a sterile gauze pad. 
• Never apply pressure to the gauze until the needle is clear of the puncture site and away from 
the arm. 
• Have the respondent hold the gauze pad with mild pressure and sit quietly for a few minutes.  
• Slide the needle safety guard forward to prevent an accidental needle stick. Discard the entire 
used needle assembly in a sharps container.  
• Check the venipuncture site. If it is adequately clotted, remove the gauze and apply a bandage. 
If after a few minutes, bleeding continues keep direct pressure on the site for 5 minutes. 
• Encourage the respondent to sit quietly for a few minutes. Due to a fasting blood draw 
encourage the respondent to eat a snack if needed. 
 
When the first attempt at blood collection was unsuccessful, FEs were allowed to ask to draw blood 
from the opposite arm. However, no more than two blood collection attempts were permitted. 
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Moreover, only the antecubital fossa was acceptable for blood draw. FEs were not allowed to collect 
blood from any other sites, such as the back of the hand. 
 
Either 5 or 6 tubes of blood were collected per respondent, depending on eligibility for a separate 
glucose sub-study (see Measures of Glucose Homeostasis User Guide, Section 4.1.2.1). Collection order, 
tube type, and processing information are listed below (Exhibit 2). 
 






1 8.5 ml SST Yes Serum Discarded 
Assays: glucose, total 
cholesterol, high- & low- 
density lipoprotein-
cholesterol, triglycerides, 
high sensitivity C reactive 
protein, creatinine & 
cystatin C 
2 10 ml EDTA Yes Plasma 
RBC/buffy 
coat 
Archival: for future use 
3 
3 or 4 ml 
EDTA 
No N/A N/A 
Assay: hemoglobin A1c 
Archival: for future use 








No N/A N/A Archival: for future use 
 
Exhibit 2. Tubes of Blood Collected 
 
 
3.3.2 Blood Processing 
 
The venous blood draw concluded the home exam. After cleaning up all supplies and equipment, FEs left 
the exam sites and were allowed a maximum of two hours before processing the blood which was 
chilled at 4⁰ C (on ice or frozen cold packs) in the interim. 
 
All FEs centrifuged specific blood collection tubes, including the 8.5 ml SST, 10 ml EDTA, and when 
collected, the 6 ml NaFl/KOx vacutainer tubes. The 3-4 ml EDTA vacutainer tube used for the HbA1c 
assay was not centrifuged. FEs centrifuged tubes for ≥ 10 min at ≥ 1300 g, depending on the capabilities 
of their centrifuge. After centrifugation, FEs used the graduated transfer pipettes included in the Blood 
Collection Kit to aliquot serum from the SST and (separately, when collected) plasma from the NaFl/KOx 
vacutainer tubes into 10 ml, round bottom, skirted transport tubes (BD Biosciences, NJ). FEs aliquoted as 
much supernatant as possible into the transport tubes but avoided disturbing the precipitate layer. A 
red cap identified transport tubes containing serum from the SST vacutainer tubes, a blue cap identified 
transport tubes containing plasma from the 10 ml EDTA vacutainer tube, and a white cap identified the 
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transport tube containing plasma from the Na/Fl/KOx tube. Transport tubes were chilled at 4⁰ C (on ice 





Exhibit 3. Blood Processing Protocol 
 
After processing the blood, FEs took a loose barcode label provided in the Blood Collection Kit and 
affixed it to a paper manifest designed to accompany the transport tubes to LCBR. The loose barcode 
label matched the barcode labels on the transport tubes and the Shipping Box. FEs recorded all 
vacutainer tubes that were collected and identified all difficulties during blood draw or processing on 
the manifest as well as in the tablet. The barcode-labelled manifest was designed to be scanned on 
arrival at LCBR to associate it with an individual respondent’s transport tubes.  
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3.3.3 Shipment of Samples 
 
Immediately before shipment, FEs removed two cold packs from the freezer, sandwiched the transport 
tubes between them, enclosed the sandwich within the Styrofoam Box, placed the manifest on top of 
the Styrofoam Box, sealed the cardboard Shipping Box around it, put the cardboard Shipping Box inside 
the Tyvek envelope, applied a pre-printed FedEx shipping label to the envelope, carried it to a FedEx 
office, and handed it to a FedEx representative (in person) for Priority Overnight shipment to LCBR with 
arrival the following morning.  FEs were not permitted to leave shipments at unattended FedEx drop 
boxes.  
 
When overnight shipment was impossible, FEs noted this on the manifest and held unboxed transport 
tubes in a refrigerator approved for biological specimens or cooler with enough cold packs to keep them 
chilled at 4⁰ C overnight without risk of freezing (or thawing), as is possible on wet or dry ice. The 
transport tubes were packaged and shipped the next day using freshly frozen cold packs. 
 
3.3.4 Receipt of Samples at LCBR 
 
LCBR technicians specifically trained for Add Health Wave V received and immediately processed 
samples each morning. They unpacked the shipping boxes one at a time, evaluated the volume and 
quality of each transport tube, and entered them into a custom-made laboratory information 
management system (LIMS) program. 
 
After re-centrifuging the serum samples for hsCRP assays at 4° C for 10 min at 30,000 g, the technicians 
aspirated the supernatant, discarded all remaining precipitate, transferred the aspirate to pre-labelled 
tubes, and placed them in a biospecimen refrigerator for archival (in 1 ml aliquots at -80° C) or assay 
(200 ul aliquot). The LCBR technicians entered all aliquot information into the LIMS system. 
 
4. Assay and Internal Quality Control 
 




CRP is produced by the liver in response to inflammation. It also is a fairly stable protein that can be 
sensitively measured with precision using standardized laboratory procedures2. Moreover, in 
asymptomatic, intermediate-risk men aged ≤ 50 years and women ≤ 60 years, measurement of hsCRP 




All hsCRP assays were run on the same day of sample arrival at LCBR using the Siemens BNII / BN 
Prospec System (Siemens Healthcare Diagnostic Products GmbH, Marburg, Germany) and an hsCRP-
specific particle enhanced immunonephelometric assay. Serum from venous blood collected using the 
SST vacutainer tubes was introduced into the Siemens system by placing sample vials holding 200 µl of 
serum into an automatic sampling tray, after which all processes were automatically performed and 
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results output by the Siemens system. All samples were automatically run at a sample dilution of 1:20 
with N diluent. 
 
The Siemens system read barcodes on the vials to automatically determine which assays to run. In 
addition to hsCRP, Cystatin C also was run using the Siemens system. Only the hsCRP assay is described 
below. Assay protocols for Cystatin C can be found in the Add Health Renal Function User Guide. 
 
In the hsCRP assay, polystyrene particles coated with monoclonal antibodies specific to human CRP were 
aggregated when mixed with serum containing CRP. These aggregates scattered a beam of light passed 
through the sample. The intensity of the scattered light was proportional to the concentration of the 
relevant protein in the sample. The result was evaluated by comparison with a standard of known 
concentration.5 
 
Reference curves were generated by multi-point calibration. Serial dilutions of N Rheumatology 
Standard SL were automatically prepared by the instrument using N Diluent. The exact measuring range 
depended upon the concentration of the protein in each lot of N Rheumatology Standard SL. The 
analytical sensitivity of the assay was determined by the lower limit of the reference curve and 
therefore depended upon the concentration of the protein in the N Rheumatology Standard SL. A typical 
detection range for CRP was 0.175 – 9.75 mg/L for measurements performed using a sample dilution of 
1:20. The following reagents and materials were used in the assay and supplied by Siemens Healthcare 
(Newark, DE). 
 
• CardioPhase hsCRP; Cat. # OQIY21 
• N Supplementary Reagent/Precipitation; Cat. # OUMU15 
• N/T Rheumatology Control SL/1; Cat. # OQDB13 
• N/T Rheumatology Control SL/2; Cat. # OQDC13 
• Apolipoprotein Control Serum CHD; Cat. #OUPH07 
• N Rheumatology Standard SL; Cat. # OQKZ13 
• BNII Additive; Cat. # OQKY61 
• N Diluent; Cat. # OUMT65 
• Reaction Buffer; Cat. # OUMS65 
 
4.1.3 Internal Quality Control 
 
The Siemens system was maintained daily by inspecting all tubing, connections, and syringes for leaks, 
kinks, cracks, or contamination. Reaction buffers, N diluent, and wash solutions were also replaced daily. 
 
N/T Rheumatology Controls SL/1 and SL/2 and Apolipoprotein Control Serum was assayed after 
each establishment of a reference curve, the first use of a reagent vial as well as with each run 
of samples. LCBR also ran EDTA and serum controls as specimen samples each time a new standard 
curve was established. In addition to the daily quality control, LCBR used two pools of samples from 
twenty normal donors (US Biologicals, Salem, MA) in longitudinal quality control analyses. One pool was 
an EDTA plasma normal donor pool (Lot #E050115). The other pool was a serum normal donor pool (Lot 
#S042715).  LCBR periodically assayed both pools over the course of Wave V. The plasma and serum 
hsCRP concentration mean (coefficient of variation) based on those assays was 4.6 μg/dl (6.3%) and 7.3 
μg/dl (7.9%), respectively. When hsCRP concentrations exceeded acceptable parameters, the Siemens 
system was investigated and repaired.  
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5. External Quality Control 
5.1 Reliability 
 
Within a race/ethnicity- and sex-stratified random sample of 94 Add Health respondents among whom 
venous blood was collected twice, on average 14.3 (95% confidence interval: 13.0-15.6) days apart, 
typically by the same FE and at approximately the same time of day, the reliability of hsCRP (mg/L) was 
estimated as an intra-class correlation coefficient (ICC, 95% confidence interval) [Exhibit 4].  The 
estimate suggests that the home exam venous blood collected at Add Health Wave V yields a more 
reliable measure of hsCRP than the dried capillary whole blood spots collected at Wave IV.   
 
Measure n ICC 95% CI 
hsCRP (mg/L)  94 0.82 (0.75, 0.89) 
 








6. Constructed Measures 
6.1 Classification of hsCRP [H5CCRP] 
 
The classification of hsCRP concentrations among Add Health respondents was constructed without 
regard to fasting status, in accordance with the American Heart Association/Centers for Disease 
Control (AHA/CDC) clinical and public health practice recommendations regarding markers of 
inflammation and cardiovascular disease.2  In keeping with the recommendations, classes of hsCRP 
were defined to approximate tertiles in the adult population, as tabulated below, although it should be 




(mg/L) AHA/CDC Class 
1 < 1 Low 
2 1 – 3 Average 
3 > 3 High 
   
Exhibit 5. Classification of hsCRP 
 
6.2 Count of Common Subclinical Symptoms [H5SUBCLN] 
 
High hsCRP concentrations, particularly those exceeding 10 mg/L, should trigger searches for non-
cardiovascular (e.g. infectious or inflammatory) diseases capable of seriously confounding hsCRP-based 
estimates of cardiovascular disease risk. Subclinical sources of infection or inflammation identified in 
Question 14 of the Wave V home exam also have potential to confound hsCRP-based estimates of 
cardiovascular disease risk in apparently healthy populations. Common symptoms identified by items 
H5Q014A – H5Q014G were therefore counted and categorized as previously described 3,6,7 for 
investigation or control of potential confounding in hsCRP analyses (Exhibit 6): 
Add Health is a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the 
University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, with cooperative funding from 23 other federal agencies and foundations. Information on how to obtain the Add Health data files is 
available on the Add Health website (http://www.cpc.unc.edu/addhealth). 
13 | P a g e   
 




3 ≥ 3 
* Subclinical sources of infection or inflammation in the last 2 weeks include the 
following:  cold or flu-like symptoms [variable: H5Q014A = 1], Q014b fever 
[variable: H5Q014B = 1],  night sweats [variable: H5Q014C = 1], nausea or vomiting 
or diarrhea [variable: H5Q014D = 1], blood in stool or feces or urine [variable: 
              
    Exhibit 6. Count of Common Subclinical Symptoms 
 
6.3 Count of Common Infectious or Inflammatory Diseases [H5INFECT] 
 
Although the infectious and inflammatory diseases identified in Question 13 of the Wave V home exam 
are not included in the symptom count tabulated above, they too may confound hsCRP-based estimates 
of cardiovascular disease risk. Therefore, responses to items H5Q013A – H5Q013F from this question 
were counted and categorized for investigation or control of potential confounding in hsCRP analyses 
(Exhibit 7).  Please note that at Wave IV, the analogous constructed variable (C_INFECT) included two 
other items in the count, namely “Asthma/Chronic Bronchitis/Emphysema” and “Hepatitis C,” which 
were not captured in the Wave V home exam.  
 
 
Code Disease Count* 
 
 0 0  
 1 1  
 2 2  
 3 ≥ 3  
 * Infectious and inflammatory diseases in the last 4 weeks include the following:  
gum disease/tooth loss [variable: H5Q013A = 1],  active infection [variable: 
H5Q013B = 1], injury [variable: H5Q013C = 1],  acute illness [variable: H5Q013D = 
1], surgery [variable: H5Q013E = 1], and active seasonal allergies [variable: 
H5Q013F = 1]. 
 
Exhibit 7. Count of Common Infectious or Inflammatory Diseases 
 
6.4 Medication Use Variables [H5CRP1 – H5CRP8] 
 
Use of anti-inflammatory medications (and/or the diseases for which they are being taken) also may 
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confound hsCRP-based estimates of cardiovascular disease risk. These exposures were captured at 
Wave V in the home exam medication inventory, and for salicylates/nonsteroidal anti-inflammatory 
drugs (NSAIDs), in questions 69 and 70 of the home exam. 8 They should be used cautiously in the 
investigation or control of potential confounding in hsCRP analyses because the typical intermittency 
and brevity of anti- inflammatory medication use (e.g. for headache, menstrual cramps, muscle ache, 
etc.) and their short half-lives in the circulation reduce ability to accurately define exposure. Moreover, 
selection biases often threaten the study of non-randomized medication exposures. Respondents used ≥ 
1 medication identified by ≥ 1 of the following questions, coded therapeutic classes, or active 
ingredients (Exhibit 8): 
 
Question / Class Label Variable 
Q069=yes  
Q070=yes 
Salicylate past 24 hours or 
Non-Steroidal Anti-Inflammatory Drug (NSAID) 





NSAIDs past 4 weeks or  
Salicylate past 4 weeks or 
Any oral medication that contains NSAID or 
Salicylate as an active ingredient* in a combination 
medication past 4 weeks 
H5CRP2 
057-058-278  Cyclooxygenase-2 (COX-2) Inhibitor past 4 weeks H5CRP3 








Anti-psoriatic past 4 weeks H5CRP6 
254-104-***  
254-257-***  
Immunosuppressive agents or 
Immunosuppressive monoclonal antibodies past 4 
weeks 
H5CRP7 




NSAIDS    
• Bromfenac • Flurbiprofen • Meclofenamate • Oxaprozin 
• Diclofenac • Ibuprofen • Mefenamic 
Acid 
• Piroxicam 
• Diflunisal • Indomethacin • Meloxicam • Sulindac 
• Etodolac • Ketoprofen • Nabumetone • Tolmetin 
• Fenoprofen • Ketorolac • Naproxen  
    
Salicylates    







• Salsalate • Thiosalicylate  
    
Exhibit 8. Anti-Inflammatory Medications 
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7. The Inflammation and Immune Function Data File (bcrp5.xpt) 
7.1. Structure 
 
The structure of the disseminated inflammation and immune function data file is flat.  This means that it 
is a respondent-level data file, where each respondent has one and only one record.  The respondent’s 




The inflammation and immune function data file includes the variables below, which are described in 
the corresponding codebook documentation that also contains frequencies.  
 
Variable Name Variable Description 
AID Respondent Identifier 
H5CRP hsCRP assay result (mg/L) 
H5CCRP hsCRP AHA/CDC classification 
H5Q013A Q013a Gum disease/tooth loss in last 4 weeks 
H5Q013B Q013b Active infection in last 4 weeks 
H5Q013C Q013c Injury in last 4 weeks 
H5Q013D Q013d Acute illness in last 4 weeks 
H5Q013E Q013e Surgery in last 4 weeks 
H5Q013F Q013f Active seasonal allergies in last 4 weeks 
H5INFECT Q013 Count of infectious/inflammatory diseases 
H5Q014A Q014a Cold or Flu-like symptoms in last 2 weeks 
H5Q014B Q014b Fever in last 2 weeks 
H5Q014C Q014c Night sweats in last 2 weeks 
H5Q014D Q014d Nausea or vomiting or diarrhea in last 2 weeks 
H5Q014E Q014e Blood in stool or feces or urine in last 2 weeks 
H5Q014F Q014f Frequent urination in last 2 weeks 
H5Q014G Q014g Skin rash or abscess in last 2 weeks 
H5SUBCLN Q014 Count of subclinical symptoms 
H5CRP1    Flag indicating NSAID/Salicylate medication use (24 hours) 
H5CRP2    Flag indicating NSAID/Salicylate medication use (4 weeks) 
H5CRP3    Flag indicating Cox-2 Inhibitor medication use (4 weeks) 
H5CRP4    Flag indicating Inhaled Corticosteroid medication use (4 weeks) 
H5CRP5    Flag indicating Corticotropin/Glucocorticoid medication use (4 weeks) 
H5CRP6    Flag indicating Anti-rheumatic/Anti-psoriatic med use (4 weeks) 
H5CRP7    Flag indicating Immunosuppressive medication use (4 weeks)      
H5CRP8    Flag indicating any Anti-Inflammatory medication use (4 weeks)            
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